Algorithms for molecular testing in solid tumours

BJMO - volume 13, issue 7, november 2019

Ir A. Hébrant PhD, M. Lammens MD, PhD, C. Van den Broecke MD, N. D’Haene MD, PhD, J. Van den Oord MD, PhD, A. Vanderstichele MD, PhD, A. Dendooven MD, PhD, P. Neven MD, PhD, K. Punie MD, G. Floris MD, PhD, J. Van der Meulen MD, HA. Poirel MD, PhD, C. Dooms MD, PhD, S. Rottey MD, PhD, T. Boterberg MD, PhD, L. Brochez MD, PhD, M.C. Burlacu MD, G. Costante MD, D. Creytens MD, PhD, P. De Paepe MD, PhD, R. De Pauwn MD, B. Decallonne MD, PhD, F. Dedeurwaerdere MD, H. Denys MD, PhD, L. Ferdinande MD, PhD, R. Forsyth MD, PhD, M. Garmyn MD, PhD, T. Gevaert MD, PhD, J. De Grève MD, PhD, E. Govaerts MD, E. Hauben MD, PhD, J. Kerger MD, O. Kholmanskikh Van Criekingen MD, PhD, V. Kruse MD, PhD, Y. Lalami MD, L. Lapeire MD, PhD, P. Lefesvre MD, PhD, J.P. Machiels MD, PhD, B. Maes MD, PhD, G. Martens MD, PhD, M. Remmelink MD, PhD, I. Salmon MD, PhD, R. Sciot MD, PhD, S. Tejpar MD, PhD, K. Van de Vijver MD, PhD, L. Van de Voorde MD, I. Van den Berghe MD, A. Van den Bruel MD, K. Vandecasteele MD, PhD, L. Vanwalleghem MD, K. Vermaelen MD, PhD, R. Salgado MD, PhD, E. Wauters MD, PhD, B. Weynand MD, PhD, E. Van Valckenborgh PhD, G. Raicevic PhD, M. Van den Bulcke PhD, P. Pauwels MD, PhD


In order to advise the Federal Government on the reimbursement of molecular tests related to Personalised Medicine in Oncology, the Commission of Personalised Medicine (ComPerMed), represented by Belgian experts, has developed a methodology to classify molecular testing in oncology. The different molecular tests per cancer type are represented in algorithms and are annotated with a test level reflecting their relevance based on current guidelines, drug approvals and clinical data. The molecular tests are documented with recent literature, guidelines and a brief technical description. This methodology was applied on different solid tumours for which molecular testing is a clear clinical need.

(BELG J MED ONCOL 2019;13(7):286–95)

Read more

P.11 Outcome and relapse pattern between squamous cell and adenocarcinoma of the cervix

BJMO - 2017, issue 3, february 2017

K. Couvreur , K. Vandecasteele MD, PhD, P. Tummers , A. Makar , R. Van Den Broecke , H. Denys MD, PhD

Read more

Oligometastatic ovarian cancer successfully treated with stereotactic radiotherapy

BJMO - volume 8, issue 3, july 2014

S. Jeurissen MD, S. Bral MD, PhD, K. Vandecasteele MD, PhD, G. De Meerleer MD, PhD, H. Denys MD, PhD

A 53-year old woman presented with an ovarian cancer, FIGO stage IIIc, for which she received a (suboptimal) debulking. Chemotherapy was started, consisting of three-weekly carboplatin-paclitaxel. After four cycles, an interval-debulking was done, which revealed one positive lymph node (out of 21) located interaortocaval. Chemotherapy was resumed, until seven cycles. She had a complete remission, but after four years, she developed positive mediastinal and interaortocaval lymph nodes. She was treated with stereotactic radiotherapy, which resulted in resolution of the lesions and normalisation of the tumour marker. She has no signs of relapse after nearly two years.

This case illustrates that radiotherapy can be an important treatment option in selected patients with oligometastases.

(BELG J MED ONCOL 2014;8(3):87–90)

Read more

Introducing Intensity-Modulated Arc Therapy in the multimodality treatment of pelvic gynaecological tumours: thinking out of the box

BJMO - volume 7, issue 2, may 2013

K. Vandecasteele MD, PhD, G. De Meerleer MD, PhD


The need for an efficient, fast technique to irradiate large concave targets lead to the introduction of intensity-modulated arc therapy in the multimodality treatment of pelvic gynaecological tumours. Postoperatively irradiated cervical and endometrial cancer patients benefit by reduced toxicity rates. In locally advanced cervical cancer the use of intensity-modulated arc therapy with a simultaneously integrated boost allows for a safe hysterectomy, resulting in promising control and survival rates. In chemotherapy-resistant ovarian cancer patients with peritoneal carcinomatosis, the use of intensity-modulated arc therapy facilitates a safe whole abdominopelvic irradiation, one of the few effective solutions for patients with bowel obstruction. Continuing efforts should be made to further decrease toxicity and increase response rates and survival in the multimodality treatment of pelvic gynaecological tumours.

(BELG J MED ONCOL 2013;7(2):53–56)

Read more